Metabolism of prostaglandin E2 by human HL-60 leukemia cells.
The metabolic fate of prostaglandin E2 (PGE2) was examined in human HL-60 leukemia cells. Cytosolic fractions obtained from dimethylformamide treated HL-60 granulocytes rapidly convert exogonous PGE2 to 15-keto-PGE2. The strict requirement for NAD coupled with other characteristics of the reaction indicate that the enzyme is the NAD-dependent 15-prostaglandin dehydrogenase (15-PGDH). When intact cells are incubated with 3H-PGE2, both 15-keto-PGE2 and its subsequent metabolite, 13,14-dihydro-15-keto-PGE2 are produced. Thus, HL-60 cells express two enzymes of the major prostaglandin catabolic pathway, 15-PGDH and ketoprostaglandin delta 13-reductase.
D002460:Cell Line; D015232:Dinoprostone / Q000031:analogs & derivatives; D006801:Humans; D006911:Hydroxyprostaglandin Dehydrogenases / Q000378:metabolism; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism*; D011458:Prostaglandins E / Q000096:biosynthesis / Q000378:metabolism*
D011458:Prostaglandins E; C026346:15-ketoprostaglandin E2; C025087:15-keto-13,14-dihydroprostaglandin E2; D006911:Hydroxyprostaglandin Dehydrogenases; C035859:15-hydroxyprostaglandin dehydrogenase; D015232:Dinoprostone